Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

Биотехнологии

Ms. Michelle J. Robertson

Executive Vice President, Chief Financial Officer, Treasurer and Principal Financial & Accounting Officer

Ms. Melissa A. Kelly Behrs

Executive Vice President of Business Operations & Chief Alliance Officer

Mr. Edward E. Koval

Executive Vice President & Chief Business Officer

Dr. Faye  Feller M.D.

Executive Vice President & Chief Medical Officer

Mr. Anil  Kapur

Executive Vice President of Corporate Strategy & Chief Commercial Officer

Ms. Shannon  Odam

Senior Vice President & Chief People Officer

Dr. Andrew J. Grethlein Ph.D.

Executive Vice President & Chief Operating Officer

Mr. Scott  Samuels

Executive Vice President, Chief Legal Officer & Corporate Secretary

Ms. Aron  Feingold

Vice President of Investor Relations & Corporate Communications

Dr. John A. Scarlett M.D.

Chairman of the Board, President & Chief Executive Officer

Име	Пазарна капитализация
Comera Life Sciences Holdings, Inc.	0M
CytoTools AG	0M
Purple Biotech Ltd.	0M
Starpharma Holdings Limited	0M
Arcutis Biotherapeutics, Inc.	0M
Aditxt, Inc.	0M

Geron Corporation

Geron Corporation Списък на конкурентите

Основни конкуренти